Summary
Regeneron Pharmaceuticals, Inc. reported a net loss of $20.4 million for the first quarter of 2006, a significant increase from the $4.1 million net loss in the same period of 2005. This widening loss is attributed to a decrease in other income, primarily due to the absence of a one-time $25 million payment from sanofi-aventis received in Q1 2005 related to a collaboration agreement amendment. Total revenues saw a modest increase of $2.0 million to $18.2 million, driven by growth in both contract research and development and contract manufacturing revenues. The company is actively advancing its key product candidates, VEGF Trap (in oncology and ophthalmology) and IL-1 Trap (in inflammatory diseases), with ongoing clinical trials and strategic collaborations, particularly with sanofi-aventis for the VEGF Trap. Despite the increased net loss and ongoing substantial investment in research and development, the company maintains a healthy cash position and expects existing capital resources to sustain operations through at least mid-2008, though future funding needs remain a consideration.
Key Highlights
- 1Net loss widened to $20.4 million ($0.36/share) in Q1 2006 from $4.1 million ($0.07/share) in Q1 2005, largely due to the absence of a significant one-time payment from sanofi-aventis in the prior year.
- 2Total revenues increased by 12.3% to $18.2 million, driven by higher contract research and development revenue from sanofi-aventis and increased contract manufacturing revenue from Merck.
- 3Significant investment continues in research and development, with expenses totaling $32.1 million, focused on advancing the VEGF Trap (oncology and eye diseases) and IL-1 Trap (inflammatory diseases) programs.
- 4The company received a $25 million non-refundable, up-front payment from sanofi-aventis in January 2006 related to the expansion of their VEGF Trap collaboration to include Japan.
- 5Cash and cash equivalents, along with marketable securities, stood at $324.2 million as of March 31, 2006, providing a solid liquidity position.
- 6Regeneron anticipates its current capital resources will be sufficient to fund operations through at least mid-2008, though future financing may be required.
- 7The company adopted SFAS 123R (Share-Based Payment) effective January 1, 2006, resulting in a cumulative effect adjustment of $0.8 million that reduced the Q1 2006 net loss.